Navitoclax (ABT-263)

For research use only.

Catalog No.S1001

201 publications

Navitoclax (ABT-263) Chemical Structure

CAS No. 923564-51-6

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Navitoclax (ABT-263) has been cited by 201 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M3HRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4flOGlEPTB;MD6wNFY3QSEQvF2= MmWzV2FPT0WU
MV-4-11 NX;rOI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFztfVJKSzVyPUCuNFE2QDZizszN MmjIV2FPT0WU
NKM-1 NHn1ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrk[2c4UUN3ME2wMlAyPjl7IN88US=> NFrjPYlUSU6JRWK=
ML-2 M3\iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X2emlEPTB;MD6wNVk5OyEQvF2= NU\WdFJ[W0GQR1XS
BV-173 NELiTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7rTWM2OD1yLkCyN|E1KM7:TR?= NVfFTFEyW0GQR1XS
RS4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEK1PFch|ryP M3nFWHNCVkeHUh?=
HL-60 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnmTWM2OD1yLkCyPVA5KM7:TR?= NYexXGdHW0GQR1XS
KY821 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2raUmlEPTB;MD6wNlk4PSEQvF2= NV\hZo1NW0GQR1XS
ECC10 M1\5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL0[3dRUUN3ME2wMlA{Pzl{IN88US=> MlXpV2FPT0WU
NCI-H720 NGCwNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPmTWM2OD1yLkC0NFEyKM7:TR?= NEnWO2JUSU6JRWK=
QIMR-WIL M{O5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Th[mlEPTB;MD6wOFI5PyEQvF2= MUnTRW5ITVJ?
KG-1 M3XGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hqb2lEPTB;MD6wOFQ5PiEQvF2= NF\XTmpUSU6JRWK=
TGW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P1eGlEPTB;MD6wOFY{OyEQvF2= M4TsSnNCVkeHUh?=
ATN-1 NVv0TFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPRbJZKSzVyPUCuNFQ4OzNizszN NGHZco1USU6JRWK=
RH-18 M4XJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6zW4dKSzVyPUCuNFYxPDhizszN NGWyeoVUSU6JRWK=
EW-18 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLaTWM2OD1yLkC2PFQyKM7:TR?= M3zBTnNCVkeHUh?=
NB17 NUHjXlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMEexNlQh|ryP NV7ZZ3BCW0GQR1XS
SK-NEP-1 NXnwW4lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3tVWlKSzVyPUCuNFczOTNizszN NHrHTIRUSU6JRWK=
P12-ICHIKAWA NWLqTo97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPQOpJKSzVyPUCuNFc4PzhizszN NHXRUXhUSU6JRWK=
KARPAS-45 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorFTWM2OD1yLkC3PFE2KM7:TR?= NFz2UoxUSU6JRWK=
EW-3 M3W5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInl[5dKSzVyPUCuNFgxPTNizszN M4jj[3NCVkeHUh?=
NB13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3GTWM2OD1yLkC4NlA{KM7:TR?= M3Tu[3NCVkeHUh?=
NCI-H209 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrYTWM2OD1yLkC4O|A1KM7:TR?= Ml\CV2FPT0WU
NCI-H1092 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUCyO|Uh|ryP MVjTRW5ITVJ?
NH-12 NV7sSGh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzocXFKSzVyPUCuNVA4PDRizszN NFPqdGRUSU6JRWK=
697 M1ztd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13UR2lEPTB;MD6xNFg{QSEQvF2= MoXIV2FPT0WU
KE-37 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PGb2lEPTB;MD6xNVM4KM7:TR?= MmfiV2FPT0WU
MOLT-4 NVnKW3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzZ5Q6UUN3ME2wMlE2OTZ7IN88US=> MWfTRW5ITVJ?
CHP-134 NIjxXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMU[zNFYh|ryP M2LnOXNCVkeHUh?=
D-283MED M{DiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomyTWM2OD1yLkG3Olg3KM7:TR?= MmrOV2FPT0WU
LU-135 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX2TWM2OD1yLkG4OVUzKM7:TR?= MlzIV2FPT0WU
LU-134-A NGjpfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX1TWM2OD1yLkG4OlcyKM7:TR?= NHvRdVFUSU6JRWK=
EM-2 NVzNR|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMUm5NVgh|ryP M2G2OHNCVkeHUh?=
LU-139 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfUbHBuUUN3ME2wMlIxPDl6IN88US=> Mo\oV2FPT0WU
ALL-PO NH7w[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PLNGlEPTB;MD6yNVk5QCEQvF2= NUHmOXc5W0GQR1XS
NB12 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\HeGlEPTB;MD6yN|EyPSEQvF2= NVnXfXlHW0GQR1XS
KP-N-YN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j5UWlEPTB;MD6yN|U4OyEQvF2= NHXoZ45USU6JRWK=
BEN NFrvN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nLRWlEPTB;MD6yN|k3QCEQvF2= NITjO5dUSU6JRWK=
HCC1569 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLvdYM{UUN3ME2wMlI2OTB4IN88US=> NWC1WYV1W0GQR1XS
HuO9 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMk[3NVUh|ryP M{P0TXNCVkeHUh?=
WM-115 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm5TWM2OD1yLkK3O|M5KM7:TR?= NGHxT2hUSU6JRWK=
CCRF-CEM NUi5cpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwM{O1Nlkh|ryP MlLKV2FPT0WU
IST-SL1 NVLvTnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwM{WzOFMh|ryP M1rBbHNCVkeHUh?=
BE-13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLPGJKSzVyPUCuN|Y1PTlizszN MonxV2FPT0WU
COR-L88 NH\MZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTSZlhPUUN3ME2wMlM3PTRizszN NFz5UIZUSU6JRWK=
DOHH-2 NVzhSlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[5XWlEPTB;MD60NVAzOyEQvF2= MXrTRW5ITVJ?
A704 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLUTWM2OD1yLkSyOlch|ryP MlHsV2FPT0WU
KNS-81-FD MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL0TWM2OD1yLkS0NFE4KM7:TR?= NVjhXVZtW0GQR1XS
RPMI-8226 M1zad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTZbmNyUUN3ME2wMlQ2PjV{IN88US=> M2\Sd3NCVkeHUh?=
TGBC24TKB NIn2WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD2TWM2OD1yLkS1O|c5KM7:TR?= M1jpSXNCVkeHUh?=
NCI-H1304 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf3NJdKSzVyPUCuOFYyPTdizszN NYD0VXY6W0GQR1XS
MOLT-13 M1PsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XBTGlEPTB;MD60OlYyOyEQvF2= MkXnV2FPT0WU
EW-22 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzwXFZyUUN3ME2wMlQ3PjdzIN88US=> NGPrd|RUSU6JRWK=
MS-1 M3T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XhcWlEPTB;MD60Olk{OyEQvF2= MXLTRW5ITVJ?
RMG-I M3;ncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\3cmlEPTB;MD60PVQ3PCEQvF2= MYDTRW5ITVJ?
NTERA-S-cl-D1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmweFM2UUN3ME2wMlUxODF7IN88US=> NUDmelR4W0GQR1XS
NCI-H1048 NGryfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNUC5OVMh|ryP NUH1S4R2W0GQR1XS
SW1417 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HpcmlEPTB;MD61OVQ{QCEQvF2= MXjTRW5ITVJ?
DB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNUewPEDPxE1? NV\0[5Z2W0GQR1XS
MEG-01 NYmyU|FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETId2pKSzVyPUCuOVg{OiEQvF2= NGHL[m5USU6JRWK=
EW-13 NFjmd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDoNlJKSzVyPUCuOVg{PDFizszN MkCyV2FPT0WU
LAMA-84 NXT4[WxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOy[Id[UUN3ME2wMlU6OjB5IN88US=> MnfLV2FPT0WU
J-RT3-T3-5 NYXaO2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfJeo9KSzVyPUCuOlA5ODhizszN M2PxWXNCVkeHUh?=
MOLT-16 NV24eVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf1PI5MUUN3ME2wMlY2OjZ2IN88US=> MUnTRW5ITVJ?
DU-4475 M4fDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljQTWM2OD1yLk[1OFI4KM7:TR?= MW\TRW5ITVJ?
HAL-01 NWPTWmdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL6ToE6UUN3ME2wMlczPTR7IN88US=> M334SHNCVkeHUh?=
RD MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml62TWM2OD1yLke1PFk6KM7:TR?= NIfIe2ZUSU6JRWK=
OAW-28 NXXNSZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;zZmlEPTB;MD63PFM4KM7:TR?= NELQZnlUSU6JRWK=
HCC38 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXSS|ZKSzVyPUCuPFAyQSEQvF2= MmnyV2FPT0WU
NMC-G1 NIO0VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwOEGxNlEh|ryP NE\BOVFUSU6JRWK=
EW-16 NH6zUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDYTWM2OD1yLkixN|I5KM7:TR?= NI\PeHRUSU6JRWK=
DU-145 NFn1To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\nTGlEPTB;MD64PVkzOyEQvF2= NUCwdJl4W0GQR1XS
HPAF-II NHvNPWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor0TWM2OD1yLkmyOlI5KM7:TR?= NHLDelFUSU6JRWK=
A427 M4roZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnseWFKSzVyPUCuPVMxOjJizszN NYXhPVZDW0GQR1XS
PA-1 NXjJRW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwOUW2OFIh|ryP NIG5c2lUSU6JRWK=
OAW-42 NHy5bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ETWM2OD1yLkm2NVQ3KM7:TR?= NUmxb5UzW0GQR1XS
L-428 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fVVGlEPTB;MT6wNVI2KM7:TR?= NFHoSZJUSU6JRWK=
COLO-824 M1mxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v4VWlEPTB;MT6wNVcxQCEQvF2= NF7pTVZUSU6JRWK=
P30-OHK NFPVUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHvOFZKSzVyPUGuNFQ3QDhizszN MWjTRW5ITVJ?
NCI-H2170 NF3mV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTOcHh6UUN3ME2xMlA3OjNizszN M123U3NCVkeHUh?=
HCC2998 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;xWpdsUUN3ME2xMlA4OTN3IN88US=> M{DsOHNCVkeHUh?=
NB14 NGHNOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PLdWlEPTB;MT6xN|c1QCEQvF2= MkC0V2FPT0WU
TGBC1TKB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[5WGlEPTB;MT6xOFE2OiEQvF2= NGnRTXBUSU6JRWK=
KP-N-YS M2i0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DaO2lEPTB;MT6xOlI{PiEQvF2= MVfTRW5ITVJ?
CAL-120 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rCZmlEPTB;MT6xOlQzQSEQvF2= MmP6V2FPT0WU
SBC-1 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDvTWM2OD1zLkG5NFU{KM7:TR?= M3u4NXNCVkeHUh?=
C32 NXzCb|RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWzSpNJUUN3ME2xMlE6ODh6IN88US=> NU[zTWNQW0GQR1XS
HCC2157 M3e0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLzTHhKSzVyPUGuNVk1QTRizszN M4\nO3NCVkeHUh?=
COLO-792 M{X0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O0XmlEPTB;MT6yNFA4OSEQvF2= NX76S5pYW0GQR1XS
ES7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrXU4RKSzVyPUGuNlc6PTFizszN NV\YW4hSW0GQR1XS
HEL NFfkV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPkUWNKSzVyPUGuN|ExOjlizszN NFGyWnhUSU6JRWK=
ES4 NUTEfG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwM{S5PVgh|ryP M1O5PXNCVkeHUh?=
NCI-SNU-1 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3XnpsUUN3ME2xMlM3PTV3IN88US=> MoLOV2FPT0WU
MDA-MB-415 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rsVWlEPTB;MT6zPFg2KM7:TR?= MknSV2FPT0WU
NCI-H2342 NFfwd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnZe2hVUUN3ME2xMlQxOjZ7IN88US=> NWWxcFZ[W0GQR1XS
NB69 NH3WUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwNE[yO|Eh|ryP MULTRW5ITVJ?
D-247MG NXLJNFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Me4lKSzVyPUGuOVEyOjJizszN NXPnToZlW0GQR1XS
SCC-4 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvFdWRxUUN3ME2xMlU6QDh5IN88US=> MVPTRW5ITVJ?
HuH-7 NWXRNW93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwNkeyPVMh|ryP NEK1cZFUSU6JRWK=
A388 M4ftfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XuT2lEPTB;MT62PFczPCEQvF2= NITIWXhUSU6JRWK=
Calu-3 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwN{C2PVch|ryP NGK4OYlUSU6JRWK=
NCI-H1648 NGO2cmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fPcGlEPTB;MT63NVQyQCEQvF2= MoH2V2FPT0WU
NCI-H2052 M{\OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWxTWM2OD1zLkeyNlAyKM7:TR?= NHOyT4ZUSU6JRWK=
Ramos-2G6-4C10 NF7NfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwN{O2OVYh|ryP NXzWWoVzW0GQR1XS
DEL M{Lubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j1XmlEPTB;MT63OFY6OiEQvF2= M3:3SXNCVkeHUh?=
SNU-423 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETCS3VKSzVyPUGuO|gyPTdizszN NWC3R|hnW0GQR1XS
COR-L23 NGfMeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwN{m4O|Qh|ryP NXjDU3BXW0GQR1XS
OMC-1 M1G4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHqZmhKSzVyPUGuPFYxOTZizszN NG\mZZBUSU6JRWK=
EW-11 NWn1V4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITVU3BKSzVyPUGuPVU3PTdizszN MX7TRW5ITVJ?
HSC-3 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CyRWlEPTB;MT65OlM3PSEQvF2= Mo\lV2FPT0WU
MLMA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTjTWM2OD1zLkm2Olc4KM7:TR?= MYfTRW5ITVJ?
RCM-1 M33JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jPbWlEPTB;Mj6wNFM6QSEQvF2= MmL5V2FPT0WU
MFE-280 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS1d4E1UUN3ME2yMlAzQDR6IN88US=> NHvyVGxUSU6JRWK=
ES8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n0eGlEPTB;Mj6yOVQ4OSEQvF2= NXvleItrW0GQR1XS
TE-11 NVHpXXNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD1{LkK5OFc{KM7:TR?= NYTrU2d4W0GQR1XS
HuO-3N1 NFLSc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvZNYNKSzVyPUKuOFg4QCEQvF2= M3vsPHNCVkeHUh?=
MHH-NB-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLtU2JKSzVyPUKuOVEyPThizszN MXPTRW5ITVJ?
TGBC11TKB NFe3WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO2S3FKSzVyPUKuOVc3QDFizszN M2OwbXNCVkeHUh?=
HOP-92 NHL5eHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jQNmlEPTB;Mj61PFc1OyEQvF2= MUHTRW5ITVJ?
IGR-1 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJwNkKwN|Uh|ryP MVzTRW5ITVJ?
GOTO MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwNkWzO|ch|ryP MojpV2FPT0WU
NCI-H1650 NWX2eXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\xe2dKSzVyPUKuO|IzOTVizszN MlmxV2FPT0WU
NCI-H1581 M{P1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jXN2lEPTB;Mj63PVY5OSEQvF2= NUDDTld4W0GQR1XS
NCI-H2405 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHSRVZPUUN3ME2yMlgzPzh{IN88US=> NHvwWWlUSU6JRWK=
U-118-MG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vSNWlEPTB;Mj65OlQ6OSEQvF2= MXLTRW5ITVJ?
DoTc2-4510 NVjqT5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjSTWM2OD1|LkCxOFE4KM7:TR?= M2PIWnNCVkeHUh?=
NCI-H596 NH7pZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrmSnlYUUN3ME2zMlA1QTl5IN88US=> M3nNV3NCVkeHUh?=
MPP-89 NXXpUJprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwMEW2OlYh|ryP NUS1cWtyW0GQR1XS
GCIY NGDFTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwMkC0PVEh|ryP M2fiOXNCVkeHUh?=
SW626 NGjZZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwMkS1OFMh|ryP MlzWV2FPT0WU
OCI-AML2 NES4UXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnITWM2OD1|LkOxNlczKM7:TR?= NF;ZTGtUSU6JRWK=
NBsusSR NYfqfplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qxS2lEPTB;Mz6zOFk{QCEQvF2= NIrlR4dUSU6JRWK=
AN3-CA M1rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXmdW13UUN3ME2zMlQ1OjN6IN88US=> MlTJV2FPT0WU
EFM-19 NVfneFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KzSGlEPTB;Mz60PFM{QSEQvF2= NEC3OYlUSU6JRWK=
RVH-421 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXQbmxlUUN3ME2zMlU3QDd5IN88US=> MVzTRW5ITVJ?
5637 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j5cWlEPTB;Mz62NVExOyEQvF2= NH3le4RUSU6JRWK=
PANC-08-13 M1LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNwNkO0O|Ih|ryP NUDQbJYyW0GQR1XS
H9 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNkexOFQh|ryP MUHTRW5ITVJ?
KARPAS-299 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjQPXdKSzVyPUOuOlc{PjFizszN MW\TRW5ITVJ?
TE-5 NH[2[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fIZmlEPTB;Mz63NFcxQSEQvF2= MXTTRW5ITVJ?
NOS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPYW|VKSzVyPUOuO|k5OzRizszN MYLTRW5ITVJ?
HH M{jERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLINVNKSzVyPUOuPFM5PjhizszN NI\jN5dUSU6JRWK=
769-P NWTCcYFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwOEm1NUDPxE1? Mn3xV2FPT0WU
CHP-212 NIX2UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf0TWM2OD1|LkmyOVQ6KM7:TR?= NYjROZFNW0GQR1XS
NCI-H82 M{Xmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwOUW5N|Yh|ryP NUjYeGFNW0GQR1XS
Mo-T MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD4PIxOUUN3ME20MlA1OzF{IN88US=> NGCzc3NUSU6JRWK=
BB65-RCC NIe1fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTRwMESzPVkh|ryP M4jyOnNCVkeHUh?=
SW1990 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPBNHRkUUN3ME20MlA2QTB6IN88US=> MkDsV2FPT0WU
LK-2 NEXadG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwMUGyPVMh|ryP MUnTRW5ITVJ?
ES5 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL6UXFKSzVyPUSuNVM6QDVizszN MVHTRW5ITVJ?
JVM-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfOT21NUUN3ME20MlE5OjJ{IN88US=> MXPTRW5ITVJ?
RPMI-7951 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PFbGlEPTB;ND6yNlQyOyEQvF2= NHXZVlNUSU6JRWK=
Calu-6 M3nicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfBcYFKSzVyPUSuNlc5QDFizszN MYPTRW5ITVJ?
LC-2-ad MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv0TWM2OD12LkK5OVY5KM7:TR?= Mo[xV2FPT0WU
SW954 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILmVWhKSzVyPUSuNlk3PiEQvF2= NUW0VIpXW0GQR1XS
H-EMC-SS NXft[oNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH30NZVKSzVyPUSuN|E5OzFizszN MnjGV2FPT0WU
ES3 M3\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwM{W0OFEh|ryP Ml72V2FPT0WU
no-11 M4KwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXThdo9PUUN3ME20MlM2PTV2IN88US=> NIOxb3NUSU6JRWK=
LAN-6 M2fscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i5OGlEPTB;ND60OVE5QSEQvF2= Mm\mV2FPT0WU
FTC-133 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwNUO5OUDPxE1? M336SnNCVkeHUh?=
8505C MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwNUSyN{DPxE1? NYXzXGJGW0GQR1XS
SW620 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ITWM2OD12LkW3NFU4KM7:TR?= NIHXSWpUSU6JRWK=
BCPAP NF\SeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq5dY5nUUN3ME20MlY{PDhzIN88US=> NEKw[4tUSU6JRWK=
SK-LU-1 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjkTWM2OD12Lk[2NFg6KM7:TR?= NF\BUZhUSU6JRWK=
NCI-H1623 NXzaZWtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe0fYVKSzVyPUSuO|AzOjhizszN MXTTRW5ITVJ?
C2BBe1 NFHMXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fWdGlEPTB;ND63OFAxQCEQvF2= NE\Yc|BUSU6JRWK=
GP5d NG\pWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXie|dKSzVyPUSuO|g{QDhizszN NUfhXHhGW0GQR1XS
NB6 NUGzWZNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP2TWM2OD12Lki2NlA1KM7:TR?= MnHsV2FPT0WU
MDA-MB-157 M1HCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjKbY5UUUN3ME20Mlg5PzZizszN MYjTRW5ITVJ?
UMC-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3RTWM2OD12Lki4PVY1KM7:TR?= M3HVbXNCVkeHUh?=
HCC1419 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{juR2lEPTB;ND65NFA3OyEQvF2= M2f0VnNCVkeHUh?=
NCI-H2029 M4nQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRwOUSxPFUh|ryP MWXTRW5ITVJ?
LXF-289 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnVdmZkUUN3ME21MlA{PzF7IN88US=> NXTSe29lW0GQR1XS
KINGS-1 NXHDbYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X2NmlEPTB;NT6wO|c1PCEQvF2= MUPTRW5ITVJ?
HD-MY-Z NH3xTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W0V2lEPTB;NT6yN|k3QSEQvF2= MkX1V2FPT0WU
ESS-1 NVvBb3JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnuXldvUUN3ME21MlI2PTl5IN88US=> MonlV2FPT0WU
GI-1 NF7ZeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwMke5NlYh|ryP MkSzV2FPT0WU
RPMI-2650 M2XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlexTWM2OD13LkO2NVYh|ryP NGOwepdUSU6JRWK=
IA-LM M1:1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPFNohJUUN3ME21MlM6QDdzIN88US=> NHPiOHVUSU6JRWK=
KP-4 NWnmeXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TiU2lEPTB;NT60OlM{PCEQvF2= NHnsWlJUSU6JRWK=
G-402 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\6NWdIUUN3ME21MlUyQDZ3IN88US=> MmD0V2FPT0WU
OS-RC-2 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi4WldNUUN3ME21MlUzPjB2IN88US=> NUniN2syW0GQR1XS
NCI-H1155 M2rkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTVwNUS5OVUh|ryP MX\TRW5ITVJ?
OE19 NHzSdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lt[WlEPTB;NT62PFYzPCEQvF2= NHz1d3dUSU6JRWK=
U-2-OS NUWwWGtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTfGlEPTB;NT64PVAyOyEQvF2= NETteoxUSU6JRWK=
SCC-15 NFXzdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwOUO2OlIh|ryP NUX5Z5k1W0GQR1XS
NCI-H630 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTp[VFKSzVyPUWuPVk1ODRizszN MmKzV2FPT0WU
PFSK-1 MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLhTWM2OD14LkC1NlU6KM7:TR?= M2XvcnNCVkeHUh?=
NCI-H1770 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ziZmlEPTB;Nj6yNFg4PCEQvF2= M2LqeHNCVkeHUh?=
SK-MEL-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD5TWM2OD14LkSyPVE2KM7:TR?= M3qyN3NCVkeHUh?=
LB1047-RCC MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnEbGY2UUN3ME22MlQ4PjJ3IN88US=> M4TsfHNCVkeHUh?=
NCI-H446 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37iTWlEPTB;Nj62NlkzPSEQvF2= MX;TRW5ITVJ?
SW780 M3nBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTLTWM2OD14LkewNVg2KM7:TR?= NWLrT4dbW0GQR1XS
NEC8 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrY[JpoUUN3ME22Mlc3PjNizszN MWjTRW5ITVJ?
NOMO-1 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwN{ixNVEh|ryP M4X6VHNCVkeHUh?=
COLO-668 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXhSYlEUUN3ME22Mlg1Ozh5IN88US=> NHfpcHFUSU6JRWK=
MC116 M{PsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZwOUO4PVch|ryP NIjUcI5USU6JRWK=
HCC1937 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XhZ2lEPTB;Nj65PVI2OSEQvF2= NYf3bIEzW0GQR1XS
NCI-N87 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwVGlEPTB;Nz6xPVI6OyEQvF2= M3njVXNCVkeHUh?=
COLO-320-HSR NETZ[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn1TWM2OD15LkKyO|M5KM7:TR?= MV\TRW5ITVJ?
HCC1806 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzkfldKSzVyPUeuNlYxPDRizszN MXvTRW5ITVJ?
OVCAR-3 NFnN[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnrTWM2OD15LkOzNFM5KM7:TR?= NFPVcnVUSU6JRWK=
NUGC-3 NVfsZ5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdwM{m2PVQh|ryP MmfaV2FPT0WU
SW1783 NG\IeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPCdVNKSzVyPUeuOFMyPzVizszN MVLTRW5ITVJ?
GCT NELKSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTdwNU[5NFYh|ryP MXnTRW5ITVJ?
NCI-H2126 NXv3ZYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjDTWM2OD15LkezOlI2KM7:TR?= NF\tXnhUSU6JRWK=
MEL-HO M{\VUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjwTWM2OD15Lke3NFU1KM7:TR?= NV;TSnlSW0GQR1XS
CAPAN-1 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rxTGlEPTB;Nz63O|M2PyEQvF2= MlzpV2FPT0WU
SW756 NWDaPXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\KeGlEPTB;Nz63PFM{OyEQvF2= MV;TRW5ITVJ?
SKG-IIIa MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDJXpRKSzVyPUeuPFE5QTJizszN NUXVRWJPW0GQR1XS
HCE-T NGK3[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX0doVKSzVyPUeuPFc4QDNizszN NGKxTFBUSU6JRWK=
Ca-Ski MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjzSodKSzVyPUeuPVk{QDNizszN Mm\1V2FPT0WU
COLO-684 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRThwMEG4NVgh|ryP MX7TRW5ITVJ?
KYSE-70 NFnXTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvSTWM2OD16LkC3O|I6KM7:TR?= Mn2zV2FPT0WU
TI-73 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfJU4oxUUN3ME24MlI2QDVzIN88US=> M1fRUnNCVkeHUh?=
BT-20 M2XKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvVco5kUUN3ME24MlI3ODV{IN88US=> MX;TRW5ITVJ?
MHH-ES-1 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRThwNUG4N|Qh|ryP M2XCeHNCVkeHUh?=
TE-12 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPhTWM2OD16LkW5PVMyKM7:TR?= MnHNV2FPT0WU
YH-13 NFfqZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD16Lk[xNFA5KM7:TR?= MnrXV2FPT0WU
SF126 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrKTWM2OD16LkizPFY2KM7:TR?= NXfyOXc2W0GQR1XS
J82 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnzUnRKSzVyPUiuPVAxOzhizszN NW[0TI95W0GQR1XS
RCC10RGB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X1UWlEPTB;OD65PVU3OSEQvF2= MUTTRW5ITVJ?
SK-UT-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDITWM2OD17LkC0PVQ2KM7:TR?= Moj0V2FPT0WU
LB2241-RCC MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTlwMUmxN|ch|ryP NWnzN|Z4W0GQR1XS
LB996-RCC NV;sWYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P1XGlEPTB;OT6xPVg6KM7:TR?= Mn7BV2FPT0WU
EPLC-272H M1XBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L6V2lEPTB;OT6zO|Y2PyEQvF2= MXrTRW5ITVJ?
CTV-1 NFvOSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PqWGlEPTB;OT61OlU{OiEQvF2= M1G3VnNCVkeHUh?=
HSC-2 MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTlwNUe1OUDPxE1? NW\H[plNW0GQR1XS
SK-MEL-28 M130XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LBZ2lEPTB;OT62NVg6OyEQvF2= M{PPPHNCVkeHUh?=
MMAC-SF NYPPNGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnhNVZKSzVyPUmuOlg4PSEQvF2= M1vrdXNCVkeHUh?=
CP50-MEL-B NXPvbnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2XGlEPTB;OT63OVc5OiEQvF2= M3;xN3NCVkeHUh?=
HT-1080 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDWT|VQUUN3ME25Mlc4PzN7IN88US=> NHnOXGxUSU6JRWK=
HEC-1 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFyLkOzOVIh|ryP MUfTRW5ITVJ?
AGS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nUZWlEPTB;MUCuN|c1KM7:TR?= MmnqV2FPT0WU
GAMG NHO4NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\kTWM2OD1zMD61NVYzKM7:TR?= M1frOXNCVkeHUh?=
SW48 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zDVGlEPTB;MUCuOVE5QSEQvF2= M{DzdXNCVkeHUh?=
U031 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7XcVNjUUN3ME2xNE42QTB6IN88US=> M1G2cXNCVkeHUh?=
OVCAR-5 M4\RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFyLk[0Nlkh|ryP MX3TRW5ITVJ?
SF295 NXzFNW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorsTWM2OD1zMD62O|A1KM7:TR?= NGPsOndUSU6JRWK=
BHT-101 NIfT[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFyLkexO|ch|ryP M3\BWHNCVkeHUh?=
VMRC-RCZ NH;ObZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnrbY5KSzVyPUGxMlMzODFizszN M1;OUHNCVkeHUh?=
ACHN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nhTGlEPTB;MUGuOFIyOSEQvF2= NGLnUWtUSU6JRWK=
NCI-H526 NVLCbJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFzLkWwOFMh|ryP MoHJV2FPT0WU
MN-60 NGHkdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jRdGlEPTB;MUGuOVM6KM7:TR?= M1LsWHNCVkeHUh?=
NCI-H2291 NF;TWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjpN4xMUUN3ME2xNU42PDZ4IN88US=> NYjWUW5vW0GQR1XS
SCC-25 M1TBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\xdZg1UUN3ME2xNU44PTV4IN88US=> NHnufIZUSU6JRWK=
SK-MEL-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\FcGlEPTB;MUGuO|Y{PyEQvF2= M1X1eXNCVkeHUh?=
SN12C MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFzLkmzOVUh|ryP M2qyTXNCVkeHUh?=
NCI-H69 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3IXYZvUUN3ME2xNk41OjN2IN88US=> NW\pUVhRW0GQR1XS
ME-180 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{LkewOVQh|ryP MlLBV2FPT0WU
MC-IXC NV76T2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF{Lke1NVgh|ryP M{THXXNCVkeHUh?=
NCI-H2347 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7L[|VMUUN3ME2xNk44PjF2IN88US=> NUfHPGZNW0GQR1XS
M059J NU\GNGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S0W2lEPTB;MUKuO|czPyEQvF2= MYXTRW5ITVJ?
A2058 NUDBe|lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zMWGlEPTB;MUKuPFY5OSEQvF2= NGjFO|RUSU6JRWK=
VA-ES-BJ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF{Lki3PFUh|ryP NEfBd|dUSU6JRWK=
Ca9-22 MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv5Z|JFUUN3ME2xNk46PDVzIN88US=> M2TVeHNCVkeHUh?=
KNS-42 NXPESoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjn[XltUUN3ME2xNk46QTh2IN88US=> M1fwSXNCVkeHUh?=
LoVo NHrvdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF|LkKzNVMh|ryP M1e0bHNCVkeHUh?=
AM-38 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXITWM2OD1zMz6yOVY3KM7:TR?= MkTBV2FPT0WU
NB5 NELlUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7MTWM2OD1zMz6zO|UzKM7:TR?= MoXWV2FPT0WU
L-363 M1Xhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq2XWg{UUN3ME2xN{41ODN|IN88US=> Mlm3V2FPT0WU
SK-MEL-30 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrBdGVmUUN3ME2xOE4xPjR3IN88US=> MnHOV2FPT0WU
NCI-H1563 MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHRTllKSzVyPUG0MlYxOzlizszN NV3hTFZzW0GQR1XS
NCI-H2228 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF2Lk[wO|ch|ryP MWHTRW5ITVJ?
MFM-223 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDDTGhKSzVyPUG1MlE5OTNizszN MljLV2FPT0WU
LB831-BLC MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLDTWM2OD1zNT6yO|Y4KM7:TR?= NXz6eVVSW0GQR1XS
SW872 NUPHW|FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOx[Y9iUUN3ME2xOU4{ODh4IN88US=> MlTaV2FPT0WU
NCI-H522 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj4Nm1KSzVyPUG1MlM{ODZizszN NVjYXGFtW0GQR1XS
EW-1 NEmybGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HQdWlEPTB;MUWuOVQ3OiEQvF2= Mo\XV2FPT0WU
HN NUHHeXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\2TWM2OD1zNT61PVQzKM7:TR?= NIP0[lRUSU6JRWK=
SW837 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED3fWZKSzVyPUG1Mlc5PDdizszN MoHyV2FPT0WU
SCC-9 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH23[I1KSzVyPUG1MlgyOTRizszN MofRV2FPT0WU
MKN7 NX\nU2VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTiPZJOUUN3ME2xOU46PzN{IN88US=> NIL3c2FUSU6JRWK=
KYSE-410 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHNVo9KSzVyPUG2MlU6OSEQvF2= MX\TRW5ITVJ?
SK-N-DZ M{nMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF4Lk[xNVYh|ryP MmrWV2FPT0WU
COR-L105 NWK3b4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF4Lk[1Nlgh|ryP NInu[INUSU6JRWK=
LB2518-MEL M4rr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HldGlEPTB;MU[uPFM5QSEQvF2= NXT1WmhmW0GQR1XS
OVCAR-4 NFPmNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD1zNj64PFYzKM7:TR?= NIDqNZFUSU6JRWK=
TK10 M3iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDaTWM2OD1zNj65OFc{KM7:TR?= NYO0T|d4W0GQR1XS
KNS-62 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTFNYdqUUN3ME2xOk46Pzd5IN88US=> MmPmV2FPT0WU
RPMI-8866 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHniSoZKSzVyPUG3MlE4OzJizszN MmHWV2FPT0WU
HuP-T4 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe2e3dKSzVyPUG3MlI1QTVizszN MmPhV2FPT0WU
CGTH-W-1 M1L6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjrTWM2OD1zNz61NlE6KM7:TR?= MkDxV2FPT0WU
T-24 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme5TWM2OD1zNz61N|Q4KM7:TR?= MXHTRW5ITVJ?
HT-3 NV3hdXNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{SxOWlEPTB;MUeuOVkyPCEQvF2= MULTRW5ITVJ?
KS-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HINWlEPTB;MUeuOlc{KM7:TR?= NWL4[m57W0GQR1XS
NCI-H1792 NUHNT2NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzSTWM2OD1zNz63PVgh|ryP MkjsV2FPT0WU
ABC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjlZ|djUUN3ME2xO{45OTRzIN88US=> MX\TRW5ITVJ?
BPH-1 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF6LkG2PFUh|ryP MnHzV2FPT0WU
A431 M{XHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2SJBKSzVyPUG4MlQyOjdizszN MXjTRW5ITVJ?
T98G NUTZO3ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfLTWM2OD1zOD61NVU4KM7:TR?= MUjTRW5ITVJ?
BHY NWnJTHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\QTWM2OD1zOD64Olkh|ryP MXjTRW5ITVJ?
Capan-2 M4HDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHMTWM2OD1zOD65NFc5KM7:TR?= NETKSIJUSU6JRWK=
MDA-MB-175-VII NUXMNZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHpPWNpUUN3ME2xPE46OjB7IN88US=> Ml;ZV2FPT0WU
CAL-27 M3POSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF7LkC0PFch|ryP NXTpTY9kW0GQR1XS
AsPC-1 NX7UNnNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfUW3pKSzVyPUG5Mlg3PTdizszN MXHTRW5ITVJ?
KU812 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLaXXJzUUN3ME2xPU46PTd|IN88US=> M{nLW3NCVkeHUh?=
NCI-H441 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJyLkCwNUDPxE1? NXPl[4hIW0GQR1XS
Mewo MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJyLkGyPFgh|ryP MmnPV2FPT0WU
SK-MEL-24 NFjIcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\pTWM2OD1{MD6xOFc4KM7:TR?= NG[3PY9USU6JRWK=
NCI-H727 M3[1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHzTWM2OD1{MD6yO|A1KM7:TR?= NHjpVpFUSU6JRWK=
EKVX MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJyLk[wOkDPxE1? NH\rdIhUSU6JRWK=
RT-112 NGXEbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET0cXZKSzVyPUKwMlYyOjJizszN Mm\6V2FPT0WU
CAMA-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJyLkm4NFMh|ryP MnXBV2FPT0WU
SW900 NI\LU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfSTWM2OD1{MT6wNVQ6KM7:TR?= NXztUYFKW0GQR1XS
NCI-H23 NI\lfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDFNmkzUUN3ME2yNU4yOjd5IN88US=> M2noTnNCVkeHUh?=
SK-PN-DW NV\IPVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTqfGhKSzVyPUKxMlE3PDlizszN MmHTV2FPT0WU
BB30-HNC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HoPGlEPTB;MkGuNlc1PSEQvF2= Ml\YV2FPT0WU
VM-CUB-1 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnjU|BwUUN3ME2yNU4{PTN4IN88US=> NEf5dVJUSU6JRWK=
IST-MEL1 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T3ZmlEPTB;MkGuN|Y6OiEQvF2= M4\peXNCVkeHUh?=
CTB-1 NF\FNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3OTHVKSzVyPUKxMlQ4PTVizszN MWDTRW5ITVJ?
LCLC-103H NXu5[XdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ{LkG1PFIh|ryP M2G5XnNCVkeHUh?=
PANC-03-27 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXme3NKSzVyPUKyMlUyPjlizszN M1LBVHNCVkeHUh?=
HTC-C3 NV3RZY52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\OTWM2OD1{Mj61OVU2KM7:TR?= MYHTRW5ITVJ?
TE-8 NEnGXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHruNZhKSzVyPUKzMlI2PjVizszN M3nGeHNCVkeHUh?=
NCI-H292 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ3LkO1N|Yh|ryP MVHTRW5ITVJ?
COLO-680N M1\DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrzdZVNUUN3ME2yOU43OzJ7IN88US=> NEnKOY9USU6JRWK=
KYSE-520 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ3Lk[0OEDPxE1? MmK1V2FPT0WU
NB10 M3znSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ4LkOxNVch|ryP NI\Wdo9USU6JRWK=
NCI-H661 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHT[4xKSzVyPUK2MlQ4OTNizszN NUTz[GhMW0GQR1XS
GMS-10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnDcoVYUUN3ME2yOk45PjN6IN88US=> MU\TRW5ITVJ?
NCI-H2122 NX:2bZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDVYJKSzVyPUK2Mlk6QThizszN MluzV2FPT0WU
OVCAR-8 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ5LkC2N|gh|ryP MUTTRW5ITVJ?
DJM-1 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfNWZRKSzVyPUK3MlE1PTRizszN M2K3RnNCVkeHUh?=
UACC-893 NUjv[5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DaRmlEPTB;MkeuPVg4QCEQvF2= Mkn0V2FPT0WU
C8166 NYP0XlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW4OJVGUUN3ME2yPE43QTN6IN88US=> M1XGUnNCVkeHUh?=
NCI-H1693 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXtcYhKSzVyPUK4MlY6PzVizszN NIjUcpZUSU6JRWK=
TYK-nu Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXPOFhKSzVyPUOwMlA{PDVizszN MmfLV2FPT0WU
SW1710 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj0TWM2OD1|MD6xNlYh|ryP MVTTRW5ITVJ?
A375 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\WdGZJUUN3ME2zNE4{OjR|IN88US=> NVvENHlUW0GQR1XS
HMV-II NUjWZVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TtWmlEPTB;M{GuN|U6OiEQvF2= MUTTRW5ITVJ?
NCI-H2087 NET6ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzU5JzUUN3ME2zNU43OzV{IN88US=> NWWxXJFOW0GQR1XS
CAL-54 NUfiXml{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfTUZdKSzVyPUOxMlczPDFizszN MWLTRW5ITVJ?
HCC70 M1nVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF73dlJKSzVyPUOyMlE{QDdizszN M1GzW3NCVkeHUh?=
ES1 NX7US5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN{LkOwOlIh|ryP NHHXepVUSU6JRWK=
NCI-H1355 NEfFeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMTWM2OD1|Mz6yNFQh|ryP MX;TRW5ITVJ?
CFPAC-1 NX25OWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PSU2lEPTB;M{OuNlM{OiEQvF2= MXjTRW5ITVJ?
MKN28 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvnOG5KSzVyPUOzMlM5ODlizszN M4HJb3NCVkeHUh?=
HDLM-2 NFz6UoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN|Lk[5N|Eh|ryP NHzCR|dUSU6JRWK=
PANC-10-05 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[wU2J6UUN3ME2zOE4yODF2IN88US=> Mk\YV2FPT0WU
SAS NVjM[2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXVUJlCUUN3ME2zOE41PTZ3IN88US=> NEXXZoVUSU6JRWK=
HCC1395 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN2LkexPFYh|ryP MVXTRW5ITVJ?
8305C M{HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPKUFdKSzVyPUO1Mlg1OTVizszN NYPKcVhUW0GQR1XS
KM12 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN4Lke1OFch|ryP NVm1R5plW0GQR1XS
SW1116 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vwdGlEPTB;M{euOVk6OiEQvF2= NYnHeYh4W0GQR1XS
SK-MEL-1 NFzFWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCzTWM2OD1|OD6zN|g6KM7:TR?= NIrTVXhUSU6JRWK=
HCC2218 NHvsSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz0e3JKSzVyPUO4MlY2OTlizszN M2f3VHNCVkeHUh?=
T84 NWqzdJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDUTWM2OD1|OD63OFA6KM7:TR?= NGX4e|lUSU6JRWK=
ETK-1 NWTCWmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN7LkCyNkDPxE1? MnXmV2FPT0WU
COLO-800 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfQTWM2OD1|OT6zPFY5KM7:TR?= NHHtdVdUSU6JRWK=
CAL-12T M2LNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTuWnBKSzVyPUO5MlUzQDFizszN M3jmS3NCVkeHUh?=
ACN NEn4PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRyLkS5NVEh|ryP NE\td3dUSU6JRWK=
SJSA-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRzLkG1PVYh|ryP NGTHPW1USU6JRWK=
PSN1 M3\vdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRzLkG3OFkh|ryP NGi5cXVUSU6JRWK=
D-566MG M3LS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRzLkKwPFYh|ryP M4q0fXNCVkeHUh?=
EGI-1 NHG3NG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XaVGlEPTB;NEKuOFI5KM7:TR?= NFn2bXhUSU6JRWK=
A204 NHvUOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWxTWM2OD12Mj62N|g5KM7:TR?= MWfTRW5ITVJ?
Saos-2 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGyU|I{UUN3ME20Nk45OzZ7IN88US=> MWLTRW5ITVJ?
SNU-C2B MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ab2tKSzVyPUSzMlY5PzhizszN M3L3XHNCVkeHUh?=
HLE NVrpUmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:2VGhKSzVyPUS0MlA5PTZizszN NWD1SZlVW0GQR1XS
SW1463 NWLyeIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[1TWM2OD12ND65PVcyKM7:TR?= NFu1PJFUSU6JRWK=
DSH1 NXrNRpVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O4SGlEPTB;NEWuNFA{OyEQvF2= NHvPVppUSU6JRWK=
MCF7 NUjVO2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP4doY6UUN3ME20OU42ODVzIN88US=> M2fFPHNCVkeHUh?=
K5 M3j3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHieGhKSzVyPUS1Mlk1ODVizszN MXjTRW5ITVJ?
NCI-H358 NVO1W5FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHPNYdKSzVyPUS3MlIyPSEQvF2= NEL2[ZZUSU6JRWK=
NCI-H2030 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTR5LkKzO|Qh|ryP M1njdXNCVkeHUh?=
SW948 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR5LkS2OEDPxE1? M1;zdHNCVkeHUh?=
BALL-1 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXUTWM2OD12Nz62NVY5KM7:TR?= Mk\JV2FPT0WU
TE-9 NXW3cGdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrVXohKSzVyPUS3Mlk2QDFizszN MXHTRW5ITVJ?
SK-N-FI NYDYfWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfVTWM2OD12OD6wN|U5KM7:TR?= NVLo[ZQyW0GQR1XS
KALS-1 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq4TWM2OD12OD6xNlg6KM7:TR?= NH2zNGpUSU6JRWK=
HO-1-N-1 M2qxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR6Lke0OFUh|ryP Mn;TV2FPT0WU
NCI-H2452 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzUTWNKSzVyPUS5MlEyPTJizszN NXfmeHVTW0GQR1XS
OC-314 NFnFOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvDTWM2OD12OT62PFM1KM7:TR?= NFjPNnRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

- Collapse
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04480086 Not yet recruiting Drug: Mivebresib|Drug: Navitoclax|Drug: Ruxolitinib Myelofibrosis (MF) AbbVie July 31 2020 Phase 1
NCT04454658 Not yet recruiting Drug: ABBV-744|Drug: Navitoclax|Drug: Ruxolitinib Myelofibrosis (MF) AbbVie July 14 2020 Phase 1
NCT04041050 Recruiting Drug: Navitoclax|Drug: Ruxolitinib Myeloproliferative Neoplasm AbbVie November 8 2019 Phase 1
NCT03181126 Active not recruiting Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Active not recruiting Drug: Navitoclax|Drug: Osimertinib Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Drug: ABT-263 Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax|Navitoclax ic50|Navitoclax price|Navitoclax cost|Navitoclax solubility dmso|Navitoclax purchase|Navitoclax manufacturer|Navitoclax research buy|Navitoclax order|Navitoclax mouse|Navitoclax chemical structure|Navitoclax mw|Navitoclax molecular weight|Navitoclax datasheet|Navitoclax supplier|Navitoclax in vitro|Navitoclax cell line|Navitoclax concentration|Navitoclax nmr|Navitoclax in vivo|Navitoclax clinical trial|Navitoclax inhibitor|Navitoclax Apoptosis inhibitor|Navitoclax does
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID